Roche Holding AG Share Price

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 09:00:22 13/06/2024 pm IST 5-day change 1st Jan Change
245.8 CHF +0.94% Intraday chart for Roche Holding AG +3.23% +0.53%

Financials

Sales 2024 * 60.63B 67.81B 5,663B Sales 2025 * 64.03B 71.62B 5,980B Capitalization 199B 222B 18,562B
Net income 2024 * 13.26B 14.83B 1,239B Net income 2025 * 14.76B 16.51B 1,379B EV / Sales 2024 * 3.51 x
Net Debt 2024 * 13.77B 15.4B 1,286B Net Debt 2025 * 8.84B 9.88B 825B EV / Sales 2025 * 3.24 x
P/E ratio 2024 *
14.5 x
P/E ratio 2025 *
13.1 x
Employees 1,03,605
Yield 2024 *
3.98%
Yield 2025 *
4.09%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day+0.94%
1 week+3.23%
Current month+6.41%
1 month+7.90%
3 months+1.99%
6 months-2.71%
Current year+0.53%
More quotes
1 week
238.60
Extreme 238.6
246.00
1 month
224.60
Extreme 224.6
246.00
Current year
212.90
Extreme 212.9
255.90
1 year
212.90
Extreme 212.9
281.30
3 years
212.90
Extreme 212.9
404.20
5 years
212.90
Extreme 212.9
404.20
10 years
206.35
Extreme 206.35
404.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 01/03/01
Chairman 57 01/08/01
Director of Finance/CFO 57 01/11/01
Members of the board TitleAgeSince
Director/Board Member 72 03/15/03
Director/Board Member 59 -
Director/Board Member 66 01/96/01
More insiders
Date Price Change Volume
13/24/13 245.8 +0.94% 1,248,111
12/24/12 243.5 +0.79% 1,065,666
11/24/11 241.6 +0.79% 1,004,984
10/24/10 239.7 -1.20% 1,202,511
07/24/07 242.6 +1.89% 1,516,994

Delayed Quote Swiss Exchange, June 13, 2024 at 09:00 pm IST

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
245.8 CHF
Average target price
278.1 CHF
Spread / Average Target
+13.12%
Consensus